Breaking the Dilemma of Margins in Breast-Conserving Surgery: SHAVE Series Research Confirms CSM Significantly Reduces Re-excision Rates, but Long-term Survival Benefit Remains Dominated by Radiotherapy

Breaking the Dilemma of Margins in Breast-Conserving Surgery: SHAVE Series Research Confirms CSM Significantly Reduces Re-excision Rates, but Long-term Survival Benefit Remains Dominated by Radiotherapy

At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Professor Anees B. Chagpar, a Professor of Surgery at the Yale School of Medicine, delivered an important special report titled "Does resection of cavity shave margins impact survival in breast cancer patients?". Based on the famous SHAVE and SHAVE2 randomized controlled trials, the report explored the advantages of Cavity Shave Margins (CSM) in breast-conserving surgery (BCS) regarding the reduction of positive margin rates and re-excision rates. For the first time, it disclosed detailed long-term impacts on patients' 5-year local recurrence (LR) rates, disease-free survival (DFS), and overall survival (OS), providing key evidence-based support for treatment de-escalation and multi-modal synergy in the field of breast surgery.
EHA Reflections | Dr. Jing Pan: Novel Nanobody-Based Dual-Epitope CD5 CAR-T Uses Speed to Redefine T-ALL Immunotherapy

EHA Reflections | Dr. Jing Pan: Novel Nanobody-Based Dual-Epitope CD5 CAR-T Uses Speed to Redefine T-ALL Immunotherapy

Treatment options remain extremely limited for patients with relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL) who relapse after CD7 CAR-T therapy. Although previous studies of humanized CD5 CAR-T cells demonstrated encouraging antitumor activity, long-term follow-up revealed a significant safety challenge: a high incidence of severe and sometimes fatal infections.
EHA Reflections | Professors Huilai Zhang and Junlei Jia: Decoding the Biological Landscape of Primary Breast DLBCL to Advance Precision Risk Stratification and Long-Term Disease Management

EHA Reflections | Professors Huilai Zhang and Junlei Jia: Decoding the Biological Landscape of Primary Breast DLBCL to Advance Precision Risk Stratification and Long-Term Disease Management

Primary breast diffuse large B-cell lymphoma (PB-DLBCL) is a rare extranodal subtype of DLBCL characterized by unique clinicopathological features and an increased risk of central nervous system (CNS) relapse. Due to its low incidence, comprehensive investigations into its biological characteristics have remained limited.
EHA Reflections | Professor Fengkui Zhang: Oral Factor B Inhibitor Shows Superior Efficacy and May Redefine First-Line Treatment for PNH

EHA Reflections | Professor Fengkui Zhang: Oral Factor B Inhibitor Shows Superior Efficacy and May Redefine First-Line Treatment for PNH

Complement C5 inhibitors have transformed the management of paroxysmal nocturnal hemoglobinuria (PNH) and remain the current standard first-line therapy. However, despite effective control of intravascular hemolysis, many patients continue to experience persistent anemia, limited hemoglobin recovery, and clinically significant extravascular hemolysis, leaving substantial unmet medical needs.
Breaking Biomarker Barriers: ASCENT-03 Study Confirms Universal Advantage of Sacituzumab Govitecan in 1L TNBC

Breaking Biomarker Barriers: ASCENT-03 Study Confirms Universal Advantage of Sacituzumab Govitecan in 1L TNBC

Triple-negative breast cancer (TNBC) has always been a challenge in clinical treatment due to its high heterogeneity, high risk of recurrence, and poor prognosis. For patients with first-line (1L) advanced TNBC who are not eligible for immune checkpoint inhibitors (PD-1/L1 inhibitors), the benefits of traditional single-agent chemotherapy are limited. The emergence of antibody-drug conjugates (ADCs) has brought new hope to this population. As the world's first approved ADC targeting Trop-2, Sacituzumab Govitecan (SG) has already demonstrated significant advantages in advanced TNBC patients who failed multiple prior lines of therapy (ASCENT study). At a recent academic conference, Professor Carlos H. Barrios from the PUCRS School of Medicine in Porto Alegre, Brazil, presented the latest biomarker subgroup analysis from the ASCENT-03 study. This analysis deeply explored the differences in efficacy between SG and chemotherapy in the first-line setting across different Trop-2 expression levels, BRCA mutation statuses, and HER2 expression statuses. This article summarizes its core academic content to provide clinical physicians with a basis for decision-making in precision therapy.
EHA Reflections | Professor Lei Fan’s Late-Breaking Oral Presentation: World’s First In Vivo Dual-Target CAR-T LB2501 Reshapes the Treatment Landscape for Lymphoma

EHA Reflections | Professor Lei Fan’s Late-Breaking Oral Presentation: World’s First In Vivo Dual-Target CAR-T LB2501 Reshapes the Treatment Landscape for Lymphoma

At the 2026 European Hematology Association (EHA) Congress, the field of cellular therapy witnessed a landmark breakthrough. During a prestigious Late-Breaking Oral Session, Professor Lei Fan from Jiangsu Provincial People's Hospital presented the first-ever clinical proof-of-concept data for LB2501, the world's first in vivo CD19/CD20 dual-target CAR-T therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL).
A New Era Begins: World’s First Bispecific ADC Iza-bren Approved, Redefining Cancer Treatment and Delivering Early Benefits to Chinese Patients

A New Era Begins: World’s First Bispecific ADC Iza-bren Approved, Redefining Cancer Treatment and Delivering Early Benefits to Chinese Patients

In June 2026, China's National Medical Products Administration (NMPA) approved iza-bren (brand name: Yizekang®; generic name: Loncastuximab Eglonatamab), a first-in-class EGFR×HER3 bispecific antibody-drug conjugate (ADC) independently developed by Biokin Pharmaceutical. The approval is for the treatment of patients with relapsed or metastatic nasopharyngeal carcinoma (NPC) following prior therapy.
EHA 2026 | Dr. Yajing Zhang: Moving from Empirical Treatment Toward Mechanism-Driven Precision Stratification in Relapsed/Refractory Hematologic Malignancies

EHA 2026 | Dr. Yajing Zhang: Moving from Empirical Treatment Toward Mechanism-Driven Precision Stratification in Relapsed/Refractory Hematologic Malignancies

The 2026 European Hematology Association (EHA 2026) Congress was held in Stockholm, Sweden, from June 11–14, 2026. Dr. Yajing Zhang and colleagues from Beijing GoBroad Boren Hospital presented three studies at this year's meeting, focusing on two critical questions in the management of relapsed/refractory hematologic malignancies.